Kyriazoglou Anastasios, Kaparelou Maria, Goumas Georgios, Liontos Michael, Zakopoulou Roubini, Zografos Eleni, Zygogianni Anna, Dimopoulos Meletios Athanasios, Zagouri Flora
Department of Clinical Therapeutics, General Hospital Alexandra, Athens, Greece.
Department of Medical Oncology, Aghios Savvas Anticancer Hospital, Athens, Greece.
Breast Care (Basel). 2022 Feb;17(1):63-70. doi: 10.1159/000514860. Epub 2021 Mar 29.
The clinical outcome of HER2-positive breast cancer patients changed with the use of anti-Her therapies, though it still remains an aggressive and fatal disease. Implementation of immune checkpoint inhibitors in HER2-positive Breast cancer is a concept supported by the reported biological and preclinical data.
We conducted a systematic review of the current literature involving immune checkpoint inhibitors alone or in combination with targeted therapies or chemotherapy finalized or running in HER2-positive breast cancer.
Twelve clinical trials and 2 case reports were identified in our study.
The reported clinical trials highlight that checkpoint inhibition seems to be promising in metastatic, neoadjuvant, and adjuvant settings of HER2-positive breast cancer.
尽管HER2阳性乳腺癌患者使用抗HER疗法后临床结局有所改变，但它仍是一种侵袭性致命疾病。在HER2阳性乳腺癌中应用免疫检查点抑制剂这一概念得到了已报道的生物学和临床前数据的支持。
我们对目前涉及免疫检查点抑制剂单独使用或与靶向治疗或化疗联合使用、已完成或正在进行的HER2阳性乳腺癌相关文献进行了系统综述。
我们的研究中确定了12项临床试验和2例病例报告。
已报道的临床试验表明，在HER2阳性乳腺癌的转移、新辅助和辅助治疗中，检查点抑制似乎很有前景。
